Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track KALA with free AI briefings, catalyst countdowns, and dilution alerts.

KALA · KALA BIO, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$7.2M Cash on Hand
9.8mo Cash Runway
Follow KALA by email Get an email when KALA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about KALA, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

KALA holds $7.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.2M/quarter from operations, an estimated runway of 9.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 75 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KALA files for a raise →

👥 Who Owns KALA

Insiders 12.2% Other 5%+ holders 5% Institutions 11.4% Public and other holders 71.4%
HolderTypeShares% of sharesAs of
LifeSci Capital LLC Institution (13G, 5%+) 2,200,000 11.38% 2025-12-30
OXFORD FINANCE LLC
10% owner
Insider 1,620,000 8.38% 2025-11-25
Labkowski Nachum 5%+ holder (13G) 966,991 5.00% 2026-10-14
BAKER BROS. ADVISORS LP
Former 10% owner
Insider 425,006 2.20% 2025-09-30
Mark T Iwicki
Director · +104,950 options
Insider 103,540 0.54% 2025-10-23
Darius Kharabi
CHIEF BUSINESS OFFICER · +45,200 options
Insider 41,760 0.22% 2025-10-22
Romulus K Brazzell
Head of Research and Development and Chi · +45,200 options
Insider 35,952 0.19% 2025-10-22
Todd Bazemore
Director · +270,400 options
Insider 35,933 0.19% 2025-10-22
Mary Reumuth
CHIEF FINANCIAL OFFICER
Insider 28,906 0.15% 2025-10-22
Andrew I Koven
Director · +6,850 options
Insider 16,972 0.09% 2025-06-15
Howard B Rosen
Director · +5,450 options
Insider 16,502 0.09% 2025-06-15
Gregory D Perry
Director · +5,450 options
Insider 13,344 0.07% 2025-06-15

Share count 19,339,786 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full KALA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KALA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.